Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Azoitei, Ninel, Hoffmann, Christopher M., Ellegast, Jana M., Ball, Claudia R., Obermayer, Kerstin, Gößele, Ulrike, Koch, Britta, Faber, Katrin, Genze, Felicitas, Schrader, Mark, Kestler, Hans A., Döhner, Hartmut, Chiosis, Gabriela, Glimm, Hanno, Fröhling, Stefan, Scholl, Claudia
Formato: Artigo
Idioma:Inglês
Publicado em: The Rockefeller University Press 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328372/
https://ncbi.nlm.nih.gov/pubmed/22451720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados